Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
In an effort to extend its offerings, Royal Bank of Canada (RY - Snapshot Report) plans to acquire the Shoppers Optimum MasterCard credit card portfolio from Bank of America Corp. (BAC - Analyst Report). The announcement comes with the launch of the co-branded MasterCard offered by Royal Bank of Canada (“RBC”) and Shoppers Drug Mart Corporation, a leading pharmacy chain in Canada.
The co-branded card, RBC Shoppers Optimum MasterCard, further consolidates RBC’s alliance with Shoppers and complements the RBC Shoppers Optimum banking account and debit card.
Financial terms of the deal for the purchase of the credit card portfolio were not made public. It is subject to customary regulatory approvals as well as other conditions and is anticipated to be accomplished later this fall.
Following the closure of the deal, RBC intends to move the existing Shoppers Optimum MasterCard credit cards into the RBC Shoppers Optimum MasterCard credit card program. With no annual fees and the option of earning reward points for procurement, the co-branded card is expected to garner popularity and strengthen the customer base.
The deal is a strategic fit for RBC. It will not only help increase its MasterCard product offerings, but also bolster its customer base and facilitate revenue generation amidst the stressed conditions in their lending business.
On the other hand, Bank of America has been involved in restructuring its business and has made several asset sales in the past few years as part of its effort to rebound from the financial crisis and build up its capital levels. As a matter of fact, last year, the company vended its Canadian consumer credit card business to Toronto-Dominion Bank. Also, for Shoppers Drug Mart, the deal will help increase the financial flexibility of its customers and add to its competitive edge.
The shares of RBC retain a Zacks #2 Rank, which translates into a short-term Buy rating.
Get the full Analyst Report on BAC - FREE
Get the full Snapshot Report on RY - FREE